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The intricate system of serum complement pro-
teins provides resistance to infection. A pivotal
step in the complement pathway is the assem-
bly of a C3 convertase, which digests the C3
complement component to form microbial
binding C3 fragments recognized by leuko-
cytes. The spleen and C3 provide resistance
against blood-borne S. pneumoniae infection.
To better understand themechanisms involved,
we studied SIGN-R1, a lectin that captures mi-
crobial polysaccharides in spleen. Surprisingly,
conditional SIGN-R1 knockout mice developed
deficits in C3 catabolism when given S. pneu-
moniae or its capsular polysaccharide intra-
venously. There were marked reductions in
proteolysis of serumC3, deposition of C3 on or-
ganismswithin SIGN-R1+ spleenmacrophages,
and formation of C3 ligands. We found that
SIGN-R1 directly bound the complement C1
subcomponent, C1q, and assembled a C3 con-
vertase, but without the traditional requirement
for either antibody or factor B. The transmem-
brane lectin SIGN-R1 therefore contributes to
innate resistance by an unusual C3 activation
pathway.
INTRODUCTION
The intricate but elegant system of complement proteins
is responsible for several innate and adaptive resistance
mechanisms. A pivotal step is the formation of a C3 con-
vertase, which catalyzes the proteolysis of complement
component, C3. The C3 convertase is formed by (1)
a ‘‘classical’’ pathway initiated by the binding of C1q to im-
munoglobulin (Ig) in immune complexes, (2) an ‘‘alterna-
tive’’ pathway triggered directly by certain microbial cellwalls and catalyzed by factor B, and (3) a soluble mannose
binding lectin pathway with many homologies to the clas-
sical C1q based pathway (reviewed in Fearon and Wong,
1983; Walport, 2001a; Walport, 2001b; Fujita, 2002). The
C3 convertase first generates C3b that is further pro-
cessed to C3bi and C3d. C3b, C3bi, and C3d serve as li-
gands or ‘‘opsonins’’ for cellular receptors on B cells,
phagocytes, and follicular dendritic cells (FDCs). Recep-
tor-mediated binding of these C3 opsonins leads to micro-
bial clearance by phagocytes (Fearon and Wong, 1983),
stimulation of B cells (Carroll, 1998), and retention of anti-
gens on FDCs (Pozdnyakova et al., 2003). C3 processing
also releases the C3a peptide, which is an anaphylatoxin
that causes smooth muscle contraction, mast cell hista-
mine release, and local inflammation. Additionally, a lytic
membrane attack complex of other complement com-
ponents C5b, 6, 7, 8 is assembled on cellular targets.
Therefore the complement system is a major pathway
for resistance and pathology, and the formation of a C3
convertase is pivotal.
The spleen clears microorganisms from the blood
stream, with Streptococcus pneumoniae representing
a major example (Amlot and Hayes, 1985; Zandvoort
and Timens, 2002). Individuals lacking a spleen are more
susceptible to infection with S. pneumoniae (Schutze
et al., 2002). Despite the development of effective treat-
ments, this gram-positive coccus has remained a signifi-
cant cause of morbidity and mortality (Garau, 2002), being
one of the most common causes of bacterial pneumonia,
otitis media, meningitis, and septicemia (Musher, 1992).
Opsonin-dependent phagocytosis via complement plays
an important role in host defense against pneumococci
(Brown et al., 1982; Brown et al., 1983). Patients with de-
ficiencies of early components of the classical pathway of
complement and C3 are at high risk for pneumococcal
disease (Picard et al., 2003). In contrast, the soluble man-
nose binding lectin binds poorly to S. pneumoniae (Neth
et al., 2000; Krarup et al., 2005), and lower lectin levels
are only weakly associated with S. pneumoniae infections
(Kronborg et al., 2002; Atkinson et al., 2004). Knockout
mice have revealed that C3 and C4 are dominantlyCell 125, 47–58, April 7, 2006 ª2006 Elsevier Inc. 47
Figure 1. SIGN-R1 Is Required for Binding of CPS to FDCs
(A) CPS14 is not bound in B cell follicles (white arrows) of 22D1 treated mice. Control and 22D1-treated mice were injected i.v. with 100 mg of CPS14
for 10, 30, 60 min. Spleen sections were stained for SIGN-R1 (green, left) and CPS14 (red). Mice were treated with 22D1 anti-SIGN-R1 mAb 24 hr
earlier or nonreactive hamster IgG control.
(B) CPS14 is fixed to CD21+ FDCs in control (yellow) but not 22D1 treated mice. 90 min after 100 mg CPS 14 i.v., spleen sections were stained for
CPS14 (red), CD21/35 (green), and SIGN-R1 (blue).
(C) Uptake of CPS (red) into MZ macrophages (white arrowheads; yellow in merge) in control and C3/ mice, but not in 22D1 treated animals, and
binding of CPS to FDCs in control mice (white arrows).required for innate resistance to S. pneumoniae, but sur-
prisingly, there is only a small or partial need for the tradi-
tional mediators of C3 fixation like factor B, mannose bind-
ing lectin, and immunoglobulin (Ig) (Brown et al., 2002;
Kars et al., 2005). Together, these findings indicate that
there is likely to be an unusual complement fixation path-
way that is independent of factor B, Ig, and mannose bind-48 Cell 125, 47–58, April 7, 2006 ª2006 Elsevier Inc.ing lectin but that nevertheless forms C3 opsonins for re-
sistance to pneumococci by phagocytes and B cells.
The spleen contains specialized regions called marginal
zones (MZ), which lie at the junction of each white pulp
nodule with the red pulp (Mebius and Kraal, 2005). The
MZ contains unique MZ B cells (Martin and Kearney,
2002) enmeshed with MZ macrophages in a reticular cell
network (Kraal and Janse, 1986). In the MZ, there is a
strongly reduced blood flow allowing intimate contact be-
tween antigens and effector cells (Guinamard et al., 2000).
The MZ thus has several functions, including the genera-
tion of antigen-specific B cell responses to T cell-indepen-
dent antigens (Humphrey, 1985) and the capture of blood-
borne pathogens (Humphrey and Grennan, 1981; Kang
et al., 2004) such as S. pneumoniae (Lanoue et al., 2004).
SIGN-R1, a C-type lectin related to DC-SIGN (Park
et al., 2001), is an uptake receptor expressed at high levels
by spleen MZ and lymph node macrophages (Geijtenbeek
et al., 2002; Kang et al., 2003). SIGN-R1 is the principal re-
ceptor for bacterial dextrans as well as the capsular pneu-
mococcal polysaccharide (CPS) of S. pneumoniae, so that
deletion of SIGN-R1 ablates clearance of these polysac-
charides by MZ macrophages (Geijtenbeek et al., 2002;
Kang et al., 2003; Kang et al., 2004; Lanoue et al., 2004).
Our approach to conditional deletion of SIGN-R1 involves
administration of the monoclonal antibody 22D1. Treat-
ment with this mAb selectively ablates SIGN-R1 expres-
sion, but not MZ macrophages, as monitored with a com-
bination of antibodies to a distinct epitope to SIGN-R1 and
other MZ receptors (Kang et al., 2004). Furthermore, Lan-
oue et al. used genetic deletion of SIGN-R1 to demon-
strate the contribution of this lectin to protection of mice
against pneumococcal septicemia (Lanoue et al., 2004).
In our continuing studies of 22D1 anti-SIGN-R1-treated
mice, we found surprisingly that, in addition to a lack of
CPS and dextran uptake in SIGN-R1+ MZ macrophages,
the polysaccharides were no longer deposited on
SIGN-R1 spleen FDCs. This suggested a link between
SIGN-R1 and the formation of C3 opsonins for FDCs.
We will show that this membrane bound lectin initiates
a classical but Ig-independent pathway for C3 fixation
by binding C1q and depositing C3 on bound polysaccha-
rides and S. pneumoniae. We suggest that this new path-
way for C3 fixation by SIGN-R1 bound polysaccharides
contributes to the role of the spleen in resistance to certain
encapsulated organisms.
RESULTS
Initial Clue that SIGN-R1 Lectin Is Involved
in C3 Fixation
To study the previously defined interaction of capsular
pneumococcal polysaccharide (CPS) with the SIGN-R1
lectin on marginal zone (MZ) macrophages of spleen
(Kang et al., 2004), we injected mice with 100 mg of
CPS14 i.v. and localized it with anti-CPS14 antibody in
sections of spleen 10 min to 1 hr later. Within minutes,
the CPS localized to SIGN-R1+ MZ macrophages, which
were identified with anti-SIGN-R1 antibodies (Kang et al.,
2003; Kang et al., 2004). However, by 1 hr the CPS was
also found in the B cell areas or follicles of the white
pulp (Figure 1A, white arrows). The follicle-associated
CPS colocalized to follicular dendritic cells (FDCs), which
are known to express CD21/CD35 complement receptors
but not SIGN-R1 (Figure 1B, yellow staining). In SIGN-R1-transient knockout mice generated by mAb 22D1 treat-
ment (Kang et al., 2004), CPS14 was not taken up by
MZ macrophages as expected, but in addition the CPS
did not localize to follicles (Figure 1A) or FDCs (Figure 1B).
This surprising finding suggested that SIGN-R1 on MZ
macrophages is needed for the deposition of CPS14 on
SIGN-R1 FDCs.
Since prior results (Harms et al., 1996) showed that CPS
binding to the MZ and FDCs was dependent on comple-
ment, probably a C3 fragment, we compared C3/ and
wild-type mice. We found that CPS14 was taken up by
SIGN-R1+ MZ macrophages in wild-type and C3/
mice (Figure 1C). However, CPS14 did not bind to FDCs
in C3/ mice (Figure 1C). Thus SIGN-R1 and C3 are
somehow both needed for CPS binding to FDCs, suggest-
ing that this lectin might contribute to C3 fixation.
SIGN-R1 Mediates Systemic Activation
of the Classical Complement Pathway
To pursue the suggestion that SIGN-R1 was required for
the formation of C3 ligands, we injected CPS or mitomy-
cin-C treated (growth inactivated) S. pneumoniae into
control and 22D1-treated mice (controls included mice
given hamster Ig, N418 anti-CD11c, and anti-Marco,
a scavenger receptor on MZ macrophages). Over the
ensuing hour, we monitored C3 processing in blood by
immunoblotting serum samples with polyclonal anti-C3
antibody. This antibody reacts with the two components
of native C3, aC3, and bC3 as well as the fragments of
aC3 that are generated during C3 processing by C3 con-
vertases (Figure 2A shows information for human C3) (Law
and Dodds, 1997). In the steady state, C3 convertase is
active so that two C3 fragments (iC3b; 70 kDa and 43
kDa) are always evident in serum. However, when pneu-
mococci or CPS were given i.v., there was rapid process-
ing of aC3 (but not bC3, which serves as a loading control
for the immunoblotting), such that the serum sample lost
most of the detectable aC3 as well as the 70 kDa iC3b
but accumulated the 43 kDa iC3b (see the two left lanes
of Figures 2B and 2C). These data in vivo are consistent
with previous results in vitro (Campbell et al., 1991). Pneu-
mococci, but not several other bacteria that we tested,
rapidly activated C3 in vivo (Figure S1). The processing
of C3 was more active with CPS from type 14 S. pneumo-
niae than CPS23 and CPS26 (data not shown), and it is
known that CPS14 binds with higher affinity to SIGN-R1
relative to CPS23 and CPS26 (Kang et al., 2004). Impor-
tantly, the activation of C3 in response to bacteria
(Figure 2B) or CPS (Figure 2C) was blocked in 22D1-
treated mice, indicating that SIGN-R1 is in large part re-
sponsible for rapid C3 convertase formation induced by
S. pneumoniae in mice.
These results were unexpected because in vitro, C3 can
be activated via the alternative pathway when S. pneumo-
niae (but not CPS) is added to serum (Winkelstein and
Tomasz, 1977), as we confirmed (Figure 2D, left; data for
CPS not shown). We also verified that C3 processing
in vitro in response to bacteria occurred similarly whenCell 125, 47–58, April 7, 2006 ª2006 Elsevier Inc. 49
Figure 2. SIGN-R1 Dominates C3 Activation by S. pneumoniae and CPS14
(A) Diagram of C3 processing by C3 convertases (MW are for human C3, but MW for rat are 120 for aC3, 70 and 43 for iC3b fragments, and 65 for bC3
(Sawant-Mane et al., 1996; Cowell et al., 2003).
(B) Analysis of C3 processing by immunoblot of serum from mice without () or with (+) 1 108 live type 14S. pneumoniae i.v. 30 min earlier (left lanes),
and in mice injected i.v. 24 hr earlier with hamster IgG, N418 hamster anti-CD11c, ED31 rat anti MARCO scavenger receptor on MZ macrophages, or
22D1 hamster anti-SIGN-R1.
(C) As in (B), but the indicated CPS were given i.v., where CPS14 binds more vigorously to SIGN-R1.
(D) Relatively slow C3 catabolism by liveS. pneumoniae type 14 added to serum from wild-type mice, or serum from mice treated 24 hr earlier with 200
mg hamster Ig or 22D1 mAb.
(E) More rapid C3 catabolism, relative to (D), when organisms were given in vivo prior to the immunoblot assay.we compared serum from wild-type mice or from mice
treated with hamster Ig or 22D1 anti-SIGN-R1 mAb 24 hr
earlier (Figure 2D). In other words, 22D1 treatment was
not consuming C3 and not preventing direct fixation of
C3 from serum by S. pneumoniae. However, the kinetics
of C3 processing was much more rapid when S. pneumo-
niae was administered in vivo, being detectable within
5 min (Figure 2E), as opposed to adding organisms to se-
rum in vitro, where 30 min were required for significant C3
catabolism (Figure 2D). Thus CPS and S. pneumoniae are
both captured within minutes from the blood by SIGN-R1+
MZ macrophages, and the latter dominate the early pro-
cessing of C3 in vivo.50 Cell 125, 47–58, April 7, 2006 ª2006 Elsevier Inc.SIGN-R1-Dependent C3 Fixation by S. pneumoniae
Type 14 In Vivo
We next wanted to verify a role for SIGN-R1 during C3 fix-
ation by S. pneumoniae directly in spleen sections in vivo.
We injected i.v. 108 CFU (colony-forming units), mitomycin
C-treated type 14 (Pn14) organisms that were also labeled
with carboxyfluorescein diacetate succinimidyl ester
(CFSE). 90 min later, to allow for uptake by MZ macro-
phages and deposition of CPS on FDCs, the spleens
were sectioned and examined by deconvolution micros-
copy. The Pn14 were taken up in the MZ in control and
C3 deficient (C3/) mice, but there were diminished num-
bers of organisms in the MZ of mice treated beforehand
Figure 3. SIGN-R1 Mediates C3 Fixation to S. pneumoniae in Spleen and Provides Resistance to Pneumococcal Infection
(A) 108 mitomycin C-treated and CFSE-labeled S. pneumoniae type 14 were injected i.v. into isotype control, 22D1 treated, and C3/ mice. 90 min
later, spleens were sectioned to show uptake of organisms into MZ (top row) and labeling for C3 (red) to show SIGN-R1-dependent C3 fixation by
bacteria as in the enlargements (yellow, bottom row). For the 22D1 treated panel, uptake into MZ macrophages is reduced, and a field is selected
to show many organisms.
(B) As in (A), but the sections were stained for C3 (red) and CD21/35 (green) to show a C3-labeled FDC network at high power (lower left).
(C) Survival times after 2  106 S. pneumoniae were injected i.v. into C4/, C3/, or CVF-treated C57BL/6 mice.
(D and E) Survival times after 2 107 live type14 S. pneumoniae were injected i.v. into C57BL/6 (B6) or BALB/c mice that were treated with hamster Ig
or 22D1 anti-SIGN-R1.with anti-SIGN-R1 mAb 22D1, possibly because there
were residual SIGN-R1 molecules and/or receptors for
the organisms in addition to SIGN-R1 (Figure 3A). C3
was deposited on the organisms in control mice in the
MZ when mice were given pneumococci but not in
C3/ mice, as expected (Figure 3A, yellow labeling). In
22D1 treated mice, when we selected regions of the MZ
where there was some uptake of CFSE-labeled S. pneu-
moniae, C3 was minimally fixed to the individual organ-
isms (Figure 3A). C3 likewise was clearly deposited on
CD21/35+ FDCs in control mice given the CFSE labeled
organisms, very little in the 22D1 treated animals, and
not at all in C3/ mice (Figure 3B). Likewise, when we
injected either CPS (or dextran, data not shown) i.v. in con-
trol mice, the polysaccharides were taken up in MZ mac-
rophages and C3 was deposited there, but again not in
22D1 treated animals (Supplemental Figure S2). Therefore
when pneumococci or polysaccharides are injected i.v.,
SIGN-R1 dominates the fixation of C3 to MZ macro-
phages and subsequently, FDCs.
Because we were using treatment with mAb 22D1 to se-
lectively deplete SIGN-R1, we needed to verify that thisapproach was relevant to the resistance of mice to infec-
tion with S. pneumoniae, as described by Lanoue et al.,
who showed that genetic deletion of SIGN-R1 decreased
innate resistance (Lanoue et al., 2004). First, we repeated
the experiments of J.S. Brown et al. (Brown et al., 2002) on
the heightened susceptibility of C3/ mice, as well as
mice treated with cobra venom factor (CVF) to deplete
C3 (Figure 3C). C4/ mice were also very susceptible to
infection, although somewhat less than the C3 deficient
mice (Figure 3C), again confirming prior results that a clas-
sical C4 dependent pathway is the dominant pathway for
C3 fixation during innate resistance (Brown et al., 2002).
Splenectomized mice were likewise very sensitive to i.v.
infection (Figure S3). 22D1 treated mice also showed a de-
crease in resistance to live S. pneumoniae in BALB/c and
C57BL/6 strains (Figures 3D,E), comparable to genetic
knockouts, but this pathway is only one of several that
contribute to C3 fixation. For example, other contributions
arise from the alternative pathway in serum (Figure 2D)
(Brown et al., 2002), natural antibody (Koppel et al.,
2005), and perhaps other lectins in the SIGN-R family
such as the related SIGN-R3 lectin (Takahara et al.,Cell 125, 47–58, April 7, 2006 ª2006 Elsevier Inc. 51
2004). Thus SIGN-R1 is one pathway for resistance to
S. pneumoniae, most likely contributing to the early phase
of C3 fixation (Figure 2B,E).
The Lectin SIGN-R1 Binds C1q from the Classical
Complement Pathway
To understand the linkage between SIGN-R1 and C3 pro-
cessing, we searched for SIGN-R1 binding proteins in the
spleen. We biotinylated the soluble extracellular domain of
SIGN-R1, which was expressed by CHO cells, to allow for
binding to streptavidin beads for 2 hr at 4ºC. Binding was
verified by the reactivity of the SIGN-R1-coated beads
with mAb 22D1. We then added 10 mg of spleen or lymph
node extracts to the SIGN-R1 coated beads, or beads
coated with transferrin as control, for 12 hr at 4ºC. The
bound proteins were eluted and separated on a 4%–
15% gradient SDS page gel and developed with silver
staining. Since the transmembrane lectin SIGN-R1 is
a mannose binding lectin (Galustian et al., 2004), we ex-
pected SIGN-R1 to retrieve proteases called MASPs,
which are soluble, mannose lectin-associated, serine pro-
teases (Fujita, 2002). Instead, the 30 kDa band that was
selectively bound to SIGN-R1-coated beads was repeat-
edly isolated and identified by MALDI-TOF peptide se-
quence analysis to be C1q, a key early component of
the classical pathway for complement fixation. Less fre-
quently, we also obtained peptide sequences for C1r
and C1s, two proteases that bind to aggregated C1q
and initiate proteolysis of the classical complement com-
ponents C2 and C4. Since SIGN-R1 is known to exist pri-
marily in an aggregated form in spleen and lymph node
(Kang et al., 2003), we reasoned that SIGN-R1 would ag-
gregate C1q, much like IgM or immune complexes, and al-
low for the initiation of the classical complement pathway.
To verify the finding of C1q binding to SIGN-R1, we de-
termined whether SIGN-R1 beads would bind C1q from
either mouse or human serum. We added 50 ml of mouse
(Figure 4A) or human serum (Figure 4B) to the SIGN-R1-
coated beads for 12 hr at 4ºC and identified C1q by immu-
noblotting with chicken anti-C1q serum, whereas no C1q
was bound to the beads coated with bovine serum albu-
min, ovalbumin, or transferrin. To clarify the mechanism
of C1q binding to SIGN-R1, the same assays were per-
formed with mouse sera genetically deficient in C1q
(C1q/), Ig (JH
/), and C3 (C3/), as well as C1q-de-
pleted human serum. As expected, C1q binding was not
found in the SIGN-R1 eluate when we applied C1q defi-
cient mouse or human serum, but C1q binding was evi-
dent with sera of JH
/ and C3/ mice (Figure 4C, left
lanes), or if purified C1q was added back to the C1q defi-
cient serum (Figure 4C, right lanes). To verify direct bind-
ing of C1q to SIGN-R1, e.g., to rule out the possible effects
of C1q binding proteins such as CRP or C1 inhibitors in
mouse or human sera, we showed that purified human
C1q bound to SIGN-R1 beads (Figure 4D). To determine
if C1q bound Ig and SIGN-R1 at similar sites, we assessed
in vitro competition for C1q binding to biotinylated SIGN-
R1 by human IgG. Human IgG blocked C1q binding to52 Cell 125, 47–58, April 7, 2006 ª2006 Elsevier Inc.SIGN-R1 as efficiently as unlabeled SIGN-R1 (Figure 4E),
implying that SIGN-R1 binds the same globular region of
C1q as Ig.
C1q Binds to SIGN-R1 on the Cell Surface
of SIGN-R1 Transfectants
To extend the studies of C1q binding to SIGN-R1, we ex-
amined cell-associated SIGN-R1, first using DCEK cell
lines stably expressing SIGN-R1 (D-SR1 in the figures)
as well as SIGN-R1 lacking its cytosolic domain (termed
D-48), the latter to help restrict binding to cell-surface (ver-
sus endocytosed) SIGN-R1. Following incubation in 10%
mouse or human serum for 1 hr at 37ºC, the cells were
washed and stained with 22D1 anti-SIGN-R1 mAb and
chicken anti-C1q polyclonal antibody. C1q was clearly
bound by both DCEK-SR1 and DCEK-48 but not to wild-
type DCEK cells (Figure 4F). Bound C1q was not observed
with C1q/ mouse serum, whereas C1q binding from
Ig/ (JH
/) serum was similar to controls (Figure S4A).
To gain more quantitative evidence, we did FACS studies.
Some C1q binding above background was noted when
mouse serum was added to wild-type DCEK cells, but
binding was increased to SIGN-R1 transfectants (Fig-
ure S4B, bottom left). Likewise, when we tested normal
human serum (NHS), we again observed increased human
C1q binding to the SIGN-R1 transfectants relative to wild-
type (Figure S4B, bottom right). We also expressed the
full-length cDNAs for mouse C1q in HEK293 cells but in-
serted a myc tag at the carboxyl terminus of C1q A chain.
The protein was expressed, as evidenced by immunoblot-
ting with polyclonal anti-C1q or monoclonal anti-myc. The
expressed C1q was again bound by SIGN-R1 transfec-
tants but not untransfected DCEK cells (Figure 4G, yellow
labeling in overlay of green myc and red SIGN-R1). Also,
when we incubated biotin conjugated-purified C1q with
DCEK cell lines without the addition of serum, only
SIGN-R1 transfectants showed binding of C1q (Figure 4H).
We also assessed C1q binding to different CHO trans-
fectants, including CHO transfected with DEC-205 and
SIGN-R3, which are other types of lectins. Only the
SIGN-R1 transfectant showed increased C1q binding
(Figure 4I). These results indicate that SIGN-R1 on trans-
fected cell lines binds both mouse and human C1q.
SIGN-R1 on Marginal Zone Macrophages Mediates
C1q Binding In Vivo
To move these findings with C1q into the mouse, we first
evaluated whether mouse C1q binds to SIGN-R1 in tissue
sections. In both control and C3/ mice, we observed
overlapping labeling for C1q and SIGN-R1 (Figure 5A).
We also noted staining for C1q in the white pulp, in the fol-
licles, and in the red pulp, as reported (Schwaeble et al.,
1995). To assess whether SIGN-R1 was required for C1q
localization, we treated mice 24 hr beforehand with 100
mg of 22D1 anti-SIGN-R1 mAb i.v. or with ED31 anti-
MARCO mAb as control. The 22D1-treated spleen no lon-
ger showed staining for C1q in the MZ, although some
C1q was noted on FDCs as in untreated mice
Figure 4. Binding of C1q to SIGN-R1 Attached to Beads or SIGN-R1-Transfected Cell Lines
(A, B, and D) 50 ml of fresh mouse serum (A), normal human serum (B), or purified C1q (D) were incubated for 2 hr at 4ºC with 5 mg of different biotin-
proteins (BSA, ovalbumin, transferrin, purified SIGN-R1) and added to 40 ml of streptavidin beads for 12 hr at 4ºC in cold PBS. Bead bound proteins
were blotted with polyclonal chicken anti-human C1q, which was detected with HRP conjugated anti-chicken IgY.
(C) As in (B), but the 50 ml of sera were from different knockout mice (C1q/, JH
/, and C3/; left) or from C1q depleted human serum to which 1 mg
of purified C1q was added (right).
(E) As in (B), but increasing doses (5, 10 mg) of transferrin (Tfe; control), human IgG, or purified SIGN-R1 were added in the above assay to test for
competition for C1q binding.
(F) 10% fresh mouse serum was incubated with DCEK cells transfected with nothing (D-WT), SIGN-R1 (D-SR1), or SIGN-R1 lacking a cytosolic
domain (D-48) for 1 hr at 37ºC. Each cell line was stained with mAb a-SIGN-R1 (green), polyclonal anti-human C1q (red), and DAPI (nuclei, blue).
(G) Mouse C1q, expressed with Myc tag at the carboxyl terminus of A chain, was applied to DCEK-WT and DCEK-SR1 transfectants for 2 hr at 37ºC.
The cells were then stained with anti-Myc (green) or control serum (not shown), anti-SIGNR1 (red), and DAPI (blue).
(H) As in (G), but 2 mg of biotin-human C1q was added for 1 hr in serum-free RPMI media prior to staining with a-SIGN-R1 (red) and strepavidin (green).
(I) C1q binding from 10% human serum to the indicated CHO transfectants by FACS analysis.(Figure 5B, arrow), presumably because other C1q recep-
tor(s) can also bind C1q. Thus, SIGN-R1 normally is re-
quired for C1q deposition in MZ macrophages in vivo.
SIGN-R1 Mediates C3 Fixation via the Classical
Pathway to SIGN-R1 Transfectants
To determine if C1q on SIGN-R1 transfectants could fix
C3, we added 3% normal or heat inactivated (HI) mouse
serum, where C3 is known to be heat-labile (Caraher
et al., 1999), and we stained the cells for mouse C3,
IgM, or IgG. The SIGN-R1 transfectants fixed C3 but not
Ig from serum, but only with normal and not HI serum(compare green and red tracings in left panels, Figure 6A).
In dose response studies, some C3 fixation was noted in
DCEK wild-type cells when the concentration of serum
was 10% of the culture medium, but SIGN-R1 transfec-
tants fixed C3 more efficiently (Figure S5, left). No C3 fix-
ation was observed when we tested C4/ and C3/ sera
(Figure S5, right), consistent with the idea that the classical
pathway was involved. Likewise, C3 fixation from serum
by mouse SIGN-R1 transfectants required C1q (Figure 6B)
but not factor B or Ig (the latter from JH
/ and RAG-1/
mice). These findings were confirmed with human serum,
where again C1q and C4 were required for C3 fixation byCell 125, 47–58, April 7, 2006 ª2006 Elsevier Inc. 53
SIGN-R1 transfectants (Figure S6). When we examined
the cells fixing C3 by microscopy, we observed consider-
able overlap in the deposits of C1q and C3 on the cell sur-
face (Figure 6C, yellow arrows). Also, when we tested
CHO cells transfected with other membrane proteins, C3
fixation only was noted with SIGN-R1 transfectants (Fig-
ure 6D). Thus cell associated SIGN-R1 fixes C3 from
mouse and human serum via the classical pathway but
independent of antibodies.
DISCUSSION
Complement-mediated opsonophagocytosis is essential
for innate immunity against invasive pneumococci. Ini-
tially, E.J. Brown et al. (Brown et al., 1983) suggested
that the alternative complement pathway is crucial. More
recently, J.S. Brown et al. (Brown et al., 2002) found that
C1q and C4 were dominant for innate resistance, rather
Figure 5. SIGN-R1-Dependent C1q Accumulation in Mouse
Spleen
(A) Sections from control and C3/ spleens were stained for SIGN-R1
(blue) and C1q (green).
(B) In parallel with (A), mice were injected with 100 mg of 22D1 a-SIGN-
R1 or with ED31 mAb to another MZ macrophage receptor, MARCO.
Sections were stained 24 hr later for SIGN-R1 (green) and C1q (red).
Arrows indicate binding of C1q to follicles.54 Cell 125, 47–58, April 7, 2006 ª2006 Elsevier Inc.than factor B, while natural IgM mediated a smaller portion
of the innate resistance to S. pneumoniae. In contrast, IgM
is typically the major route to the initiation of the comple-
ment pathway via C1q. Therefore, an unusual innate
mechanism must exist that mediates the classical C1q-
dependent pathway of complement fixation against
S. pneumoniae.
We believe that our findings identify this missing mech-
anism. It involves a transmembrane C-type lectin, SIGN-
R1, that is expressed on splenic MZ macrophages and
binds C1q as well as polysaccharides. Since SIGN-R1 is
itself aggregated in vivo (Kang et al., 2003) and is required
for C1q accumulation in MZ macrophages, we suggest
that C1q binding to SIGN-R1 is analogous to the binding
of C1q multimers to IgM or immune complexes in the
usual classical pathway for complement activation (Fig-
ure 7). In the SIGN-R1 pathway, we propose that the lectin
captures C1q, which is bound to C1r and C1s in serum,
and this in turn leads to the capture and proteolysis of
C2 and C4 to form a C3 convertase. Indeed we found
that cell-associated SIGN-R1 leads to C4-dependent but
Ig- and factor B-independent fixation of C3. When SIGN-
R1 lectin binds polysaccharides, we suggest that this or
adjacent molecules are able to form a C3 convertase
that fixes C3 from the fluid phase (Figure 7). This might oc-
cur at the cell surface or possibly within intracellular vesi-
cles, since SIGN-R1 is an endocytic receptor (Kang et al.,
2003; Kang et al., 2004). We further suspect that the pro-
cessing of C3 to form ligands for C3 receptors (opsonins)
allows for the release of opsonized polysaccharide or or-
ganisms from MZ macrophages. These can then bind to
phagocytes, B cells, and FDCs, the latter emphasized in
this paper.
The ability of the membrane bound lectin SIGN-R1 to
bind C1q and lead to C3 fixation is homologous to the sol-
uble mannose binding lectin pathway for C3 fixation (Fu-
jita, 2002). In that pathway, the lectin forms multimers
analogous to C1q, and then MASP proteases are cap-
tured that are analogous to C1r and C1s, allowing for C2
and C4 binding and C3 convertase activity. However,
there is evidence that the soluble mannose binding lectin
is not a critical player in the recognition of S. pneumoniae
(Neth et al., 2000; Krarup et al., 2005) or in defense against
this pathogen (Atkinson et al., 2004).
Instead, the membrane bound lectin SIGN-R1 seems
to be dominantly required at the level of the whole animal
for the immediate activation of C3 by S. pneumoniae upon
entry into the blood stream (Figure 2). In contrast, the di-
rect fixation of C3 from serum through the alternative
pathway is much slower and is observed with S. pneu-
moniae but not with CPS (Figure 2D). Because polysac-
charides can be recognized by the abundant SIGN-R1
on MZ macrophages, both CPS and S. pneumoniae are
within minutes of i.v. injection sequestered in the MZ
and much of the C3 in serum is catabolized (Figure 2E).
The consequences of this unusual pathway for C3 fixa-
tion, unusual because it is a classical pathway that does
not require Ig, could include lysis of the organisms,
Figure 6. C3 Fixation via SIGN-R1 by the Classical Complement Pathway In Vitro
(A) DCEK transfectants were detached with EDTA and incubated with 3% fresh mouse serum for 30 min at 37ºC. Cells were assessed by FACS for
mouse C3, IgM, and total IgG with FITC-conjugated antibodies (all green lines). Heat-inactivated human serum (HI) was a negative control for C3 fix-
ation (red dotted line on left).
(B) Binding of C3 to DCEK-WT and SR1 transfectants, incubated 1 hr with 3% of the indicated sera from knockout mice (red) or control wild-type (WT,
green) in TC buffer.
(C) After incubating both DCEK-SIGN-R1 transfectants and DCEK wild-type cells with 3% NHS in TC buffer, C1q (red) and C3 (green) binding was
assessed by staining at 4ºC for 30 min (blue is actin). Arrows indicate colocalization of C3 and C1q.
(D) C3 fixation from 10% normal human serum was assessed by FACS in the indicated CHO transfectants.capture by phagocytes, and eventual binding to C3 recep-
tors on B cells and FDCs (Figure 7), the latter emphasized
here.
C3 is known to be critical for innate resistance to
S. pneumoniae (Brown et al., 2002). We confirmed prior
research showing increased susceptibility to i.v. infection
in C3/ mice and following C3 depletion with CVF
(Figure 3D). SIGN-R1 is a major pathway for early C3
catabolism in response to i.v. injection of S. pneumoniae
and CPS (Figure 2), and SIGN-R1 contributes to innateresistance (Figures 3D and 3E). However, the effect of
SIGN-R1 removal on resistance to i.v. infection is not as
large as C3 removal. This implies that there are additional
C3-dependent pathways for resistance. While SIGN-R1
contributes to the classical C4 dependent pathway, the
latter also receives input via natural antibody (Brown
et al., 2002; Koppel et al., 2005) and perhaps other lectins
related to SIGN-R1, with SIGN-R3 being the best possibil-
ity (Takahara et al., 2004). The alternative factor B-depen-
dent pathway to C3 fixation also contributes, although it isCell 125, 47–58, April 7, 2006 ª2006 Elsevier Inc. 55
subdominant to C1q and C4 pathways in mice (Brown
et al., 2002).
Recent evidence suggests that complement and cellu-
lar-complement receptors also play important roles in
the localization and retention of nonbacterial pathogens
to FDCs, especially HIV-1 (Stoiber et al., 2001; Banki
et al., 2005) and PrPSc, a prion protein (Heppner et al.,
2001; Mabbott and Bruce, 2001). Temporary depletion
of C3 or genetic deficiency of C1q significantly delays
the onset of scrapie following peripheral infection and
reduces the early accumulation of PrPSc in the spleen, im-
plying that in the early stages of infection, C3 and C1q
contribute to the localization of scrapie infectivity in lym-
phoid tissue, i.e., a classical pathway for complement
fixation (Heppner et al., 2001; Mabbott and Bruce,
Figure 7. A Proposal for the Ig-Independent Role of SIGN-R1
in Activating the Classical Complement Pathway In Vivo
SIGN-R1 on macrophages, which binds polysaccharides and pneu-
mococci within minutes following i.v. injection, replaces the Ig that is
usually used in the classical pathway to bind C1q and then assemble
a C4 C2 convertase for C3. Limited proteolysis of C3 leads to the for-
mation of opsonins (C3b, iC3b, C3d) that fix to bacteria or to CPS,
which likewise have been bound to SIGN-R1 on macrophages. The
C3 opsonins in turn allow for binding to complement receptors on
macrophages, B cells and FDCs, which are termed CD35, CD21,
CD11b or CR1, CR2, CR3 respectively.56 Cell 125, 47–58, April 7, 2006 ª2006 Elsevier Inc.2001). Interestingly, SIGN-R1 binds viral glycoproteins,
as do human DC-SIGN and L-SIGN (Marzi et al., 2004).
While we have emphasized the role of SIGN-R1 during
complement-mediated innate resistance to pneumo-
cocci, some viruses and prions may use this new splenic
pathway for complement fixation.
EXPERIMENTAL PROCEDURES
Mice, Cells, and Reagents
Six- to ten-week-old BALB/c or C57BL/6 mice of both sexes (The
Jackson Laboratory) were kept in specific pathogen-free conditions
and studied according to institutional guidelines. Factor B/ mice
were kindly provided by Dr. Rick Wetsel (University of Texas). Splenec-
tomy was conducted according to institutional guidelines on Biometh-
odology and Surgical Techniques. Briefly, mice were anesthetized with
avertin. A 1 cm midline incision through the skin and musculature was
made just below the sternum, followed by exposure of the spleen. The
spleen was gently retracted, freed from surrounding tissue, and re-
moved by blunt dissection with mosquito forceps. The musculature
and subcutaneous tissues were closed by absorbable sutures and
metal wound clips, respectively. Sham control mice underwent this
operative procedure, only with spleens remaining intact. Mouse sera
were obtained from C1q/, JH
/, RAG-1/, factor B/, C4/,
and C3/ mice and stored at 70ºC until use as fresh or heat-inacti-
vated (56ºC, 30 min) sera. Chinese Hamster Ovary cells (CHO), human
embryonic kidney (HEK293) cells, and mouse fibroblast (DCEK) cells
were cultured in Dulbecco’s Modified Eagle Medium (for CHO and
HEK293) or RPMI 1640 (for DCEK) supplemented with 10% FCS,
100 units/ml penicillin G, and 100 mg/ml streptomycin. As described
previously (Kang et al., 2003; Kang et al., 2004), we used stable CHO
transfectants expressing cDNAs of mouse SIGN-R1, SIGN-R3,
DEC205, and human CD8 and DCEK transfectants expressing SIGN-
R1 and SIGN–R1-#48 (SIGN-R1 lacking its cytosolic domain). We pur-
chased: purified pneumococcal polysaccharides of type 14, 23, and
26 (American Type Culture Collection, Manassas, VA), streptavidin
beads (SA-beads, Amersham Biosciences, Piscataway, NJ), transfer-
rin and DAPI (Sigma-Aldrich, St. Louis, MO), endotoxin free OVA
(efOVA, SEKAGAKU Corp. Tokyo, Japan). To produce soluble SIGN-
R1 protein, we fused the sequence of a signal peptide from mouse
IgG1 to the extracellular portion of SIGN-R1 (GenBank, accession
number DQ119139), stably transfected this construct into CHO cells,
and purified SIGN-R1 from the culture supernatant by affinity to
a 22D1 anti-SIGN-R1 mAb column. The full-length cDNAs for mouse
C1q A, B, C chains were cloned by PCR and sequenced. The A chain
was modified to carry a myc tag at the carboxyl terminus. All 3 chains
of C1q were expressed together in HEK293 cells by transient transfec-
tion. We purchased human C1q as well as normal human serum (Gem-
ini Bio-Products) and sera depleted of C3, C4, C1q, factor B (Quidel
Corp). CVF (Quidel Corp) was injected i.p. 60U/kg 1 day prior to pneu-
mococcal challenge.
Antibodies and Microscopy
The generation of rabbit polyclonal antibody against the C-terminal 13
amino acid peptide of SIGN-R1 (PAb-C13) was described previously
(Kang et al., 2003). 22D1 (anti-SIGN-R1) and N418 (anti-CD11c)
hamster mAbs were purified from hybridoma culture supernatants.
We purchased antibodies to mouse C3 (FITC- or HRP-conjugated,
ICN Pharmaceuticals), human C3 (Abcam), total hamster or human
IgG and IgM (Jackson ImmunoResearch Laboratories), MARCO
(ED31 rat IgG1 mAb, SeroTec), dendritic cells (CD11c, BD Biosciences
Pharmingen), serotype 14 pneumococci (Statens Serum Institute,
Denmark), actin (Abcam, Cambridge, MA), and tubulin (SIGMA,
St. Louis, MO). Polyclonal anti-human C1q and monoclonal anti-
mouse C1q (7H8) were purchased from Abcam and HyCult biotechnol-
ogy. As secondary reagents, we used HRP-, FITC -, PE -, AMCA-, or
Alexafluore-conjugated donkey anti-chicken IgY, goat anti-hamster
IgG, donkey anti-rabbit IgG, goat anti-rat IgG, and HRP-conjugated
streptavidin from Abcam (Jackson ImmunoResearch Laboratories),
and Molecular Probes. Transfected cells and spleen sections were ex-
amined for fluoresence with a deconvolution microscope (Olympus,
Melville, NY).
Binding of C1q from Tissue Lysates and Serum
to Purified Soluble SIGN-R1
Purified soluble SIGN-R1 and control proteins were biotinylated with
EZ-Link NHS-Biotin (PIERCE) for 2 hr at 4ºC, and 5 mg of biotinylated
proteins were applied to 40 ml of streptavidin beads (SA-beads, Amer-
sham Biosciences) for 2 hr at 4ºC in PBS. Spleen and lymph node were
lysed in RIPA buffer (150 mM NaCl/50 mM TrisHCl, pH 8.0/1% Non-
idet P-40/0.5% sodium deoxycholate/0.1% SDS) supplemented with
protease inhibitor cocktails (Sigma-Aldrich, St. Louis, MO) and stored
at 80ºC. 10 mg of lysates was incubated for 12 hr at 4ºC with SIGN-
R1 or control protein coated beads. Bound proteins were eluted and
separated on a 4%–15% gradient SDS PAGE gel and developed
with silver staining. A specific band that was selectively bound to
SIGN-R1 coated beads was identified as C1q by MALDI-TOF peptide
sequence analysis (Rockefeller University Proteomics Resource Cen-
ter). In addition, to demonstrate C1q binding to SIGN-R1, 50 ml of hu-
man and mouse sera were incubated for 12 hr at 4ºC with SIGN-R1 or
control protein coated beads. Bound proteins were eluted and sepa-
rated on a 4%–15% gradient SDS PAGE gel followed by immunoblot-
ting with chicken anti-human C1q.
S. pneumoniae Strains and Fluorescent Labeling
The capsular serotype 14 (DCC1490) of S. pneumoniae was grown in
Brain Heart Infusion broth (DIFCO) to mid-log phase, inactivated with
50 mg/ml of Mitomycin-C (SIGMA, St. Louis, MO) for 1 hr, and labeled
at 109 bacteria/ml with 5 mM of CFSE (Sigma-Aldrich, St. Louis, MO)
for10 min at 37ºC. Excess CFSE was removed by extensive washing
in PBS. 1108 fluorescent bacteria were given i.v. and spleen sections
examined by deconvolution fluorescence microscopy.
Assay for In Vivo and In Vitro C3 Processing in Serum
To quantify C3 processing in serum in vivo, 1  108 S. pneumoniae or
200 mg CPS14 were injected i.v., and 40 ml of blood was collected at 0,
5, 15, and 30 min. The serum (separated at 14,000 rpm 10 min at 4ºC)
was diluted 1 to 25 with 2  SDS sample buffer with 2-mercaptoetha-
nol, boiled at 95ºC for 10 min, separated on SDS PAGE, and immuno-
blotted with polyclonal anti-mouse C3. For in vitro C3 processing, 1 
108 S. pneumoniae were incubated with 10% mouse serum in TC
buffer (140 mM NaCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM Tris, pH
7.5, supplemented with 1% BSA) for 30 min at 37ºC. The bacteria
were washed, mixed with 20ml of 2  SDS sample buffer as above
for separation on SDS-PAGE, and immunoblotted with anti-mouse C3.
Complement Binding to Cells Using FACS Analysis
After detaching with 1 mM EDTA in PBS for 10 min, cells were incu-
bated with 1%–10% mouse or human sera in TC buffer for 30 min at
37ºC. Cells were washed, incubated with antibodies for 30 min at
4ºC, and analyzed for C1q and C3 binding with a FACSCalibur flow cy-
tometer (Becton Dickinson).
Supplemental Data
Supplemental Data include six figures and can be found with this article
online at http://www.cell.com/cgi/content/full/125/1/47/DC1/.
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